Mangosteen and Diabetes

As many as 18.2 million Americans (6.3 percent of the population) have diabetes.

Each year about one million more aged 20 or older are diagnosed with the disorder.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).


Antidiabetic activity of a xanthone compound, mangiferin.

Phytomedicine. 2001 Mar;8(2):85-7. Miura T, Ichiki H, Hashimoto I, Iwamoto N, Kato M, Kubo M, Ishihara E, Komatsu Y, Okada M, Ishida T, Tanigawa K. Suzuka University of Medical Science, Mie, Japan.

Mangiferin, a xanthone, lowered the blood glucose (sugar) level in type II diabetic mice. From these findings, it seems likely that mangiferin exerts its antidiabetic
activity by decreasing insulin resistance.
--------------------------------------------------------------------------------------

Effect of mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic
rats

S. Muruganandana, , , K. Srinivasanb, S. Guptaa, P.K. Guptaa and J. Lala
aDivision of Pharmacology and Toxicology, Indian Veterinary Research Institute,
Izatnagar 243 122, UP, India bDepartment of Pharmacology and Toxicology, National Institute of PharmaceuticalEducation and Research, Mohali, Punjab, India Received 8 March 2004; revised 3November 2004; accepted 7 December 2004. Available online 5 February 2005.


In the present study, the effect of mangiferin (a xanthone glucoside, isolated from
the leaves of Mangifera indica) on the atherogenic potential of streptozotocin (STZ)-
diabetes was investigated. In addition, the effect of mangiferin on oral glucose tolerance in glucose-loaded normal rats was also determined. The chronic administration of mangiferin (10 and 20 mg/kg, i.p.) for 14 days significantly as well as markedly improved oral glucose tolerance in glucose-loaded normal rats suggesting its potent antihyperglycemic activity. The accumulating evidences suggest that both pancreatic and extrapancreatic mechanisms might be involved in its antidiabetic or antihyperglycemic action. In conclusion, the present study demonstrates that mangiferin possesses significant anti-diabetic, anti-hyperlipidemic and anti-atherogenic properties thus suggesting its beneficial effect in the treatment of diabetes mellitus associated with hyperlipidemia and related cardiovascular complications.